Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C75H94FN15O19 |
| Molecular Weight | 1528.6364 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CC(OC)=CC=C1C2=CC=C(C[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@](C)(CC3=CC=CC=C3F)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC4=CN=CN4)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CC5=CC=C(N=C5)C6=CC=CC=C6C)C(N)=O)C=C2
InChI
InChIKey=ZLVRQSAYTXYDPX-VGLKCPPXSA-N
InChI=1S/C75H94FN15O19/c1-9-44-30-48(110-8)23-24-50(44)45-21-18-42(19-22-45)28-56(67(103)83-55(64(78)100)29-43-20-25-53(80-34-43)49-16-12-10-14-39(49)2)84-68(104)57(32-61(98)99)85-69(105)58(37-92)86-70(106)62(40(3)93)89-73(109)75(7,33-46-15-11-13-17-51(46)76)91-71(107)63(41(4)94)88-59(95)36-81-66(102)54(26-27-60(96)97)87-72(108)74(5,6)90-65(101)52(77)31-47-35-79-38-82-47/h10-25,30,34-35,38,40-41,52,54-58,62-63,92-94H,9,26-29,31-33,36-37,77H2,1-8H3,(H2,78,100)(H,79,82)(H,81,102)(H,83,103)(H,84,104)(H,85,105)(H,86,106)(H,87,108)(H,88,95)(H,89,109)(H,90,101)(H,91,107)(H,96,97)(H,98,99)/t40-,41-,52+,54+,55+,56+,57+,58+,62+,63+,75+/m1/s1
| Molecular Formula | C75H94FN15O19 |
| Molecular Weight | 1528.6364 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 4 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:31:17 GMT 2023
by
admin
on
Sat Dec 16 11:31:17 GMT 2023
|
| Record UNII |
QX4U8JPV3Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
QX4U8JPV3Z
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
BMS-686117
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | Official Title: Randomized, Placebo-Controlled, Single-Dose, Crossover Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 DiabetesThe purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117. | ||
|
16158209
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY | |||
|
1122588-18-4
Created by
admin on Sat Dec 16 11:31:17 GMT 2023 , Edited by admin on Sat Dec 16 11:31:17 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
In this study, we assessed the feasibility of delivering BMS-686117, an 11-mer GLP-1 receptor peptide agonist, to the lung in rats via intratracheal administration. The pharmacokinetic profiles of three spray-dried, prototype inhaled powder formulations, 80/20 BMS-686117/trehalose (I), 100% BMS-686117 (II), and 20/80 BMS-686117/mannitol (III), as well as a lyophilized BMS-686117 powder, were compared with intravenously and subcutaneously administered peptide.
The T(max) for lung delivered peptide formulations were almost twice as fast as subcutaneous injection, suggesting potential for rapid absorption and onset of action. This study demonstrated that pulmonary delivery is a promising, non-invasive route for the administration of BMS-686117.
|
